本研究利用血管内大鼠神经胶质瘤模型，旨在分析动脉内（IA）卡铂和贝伐珠单抗递送与血脑屏障破坏（BBBB）治疗胶质母细胞瘤的疗效。C6-神经胶质瘤细胞被立体定向​​注射到左额叶威斯塔大鼠。第 8 天通过 MRI 确认肿瘤生长。第9天，在透视下将微导管从左股动脉引导至左颈内动脉。给予 2.25 mL 25% 甘露醇，然后给予 10 mg/kg 贝伐单抗或 2.4 mg/kg 卡铂。治疗后获得系列 MRI，通过分析肿瘤大小和放射组学来评估肿瘤反应。终止后进行组织学分析。对照肿瘤大鼠和IA甘露醇治疗的肿瘤大鼠出现致命的肿瘤生长，存活期分别为19.75±2.21天和36.3±15.1天。卡铂和贝伐珠单抗治疗的大鼠存活>40天，之后将它们安乐死。从连续 MRI 和组织学来看，IA 卡铂治疗的大鼠在第 35 天时表现出肿瘤消退和消退。在 IA 贝伐珠单抗治疗的大鼠中，靠近大脑基底神经节、更接近 IA 化疗注射部位的肿瘤出现消退，并重新组织了生长模式。从 MRI 来看，对照肿瘤和治疗肿瘤之间有 29 个独特的放射组学特征存在显着差异（特别是总能量和偏度），并且治疗反应者具有独特的、早期表现的放射组学特征。IA 卡铂和贝伐单抗治疗导致不同程度的肿瘤抑制，验证第一个血管内 C6 神经胶质瘤模型作为评估新 IA 疗法的可靠方法。© 作者（或其雇主）2024。禁止商业重复使用。请参阅权利和权限。英国医学杂志出版。

Utilizing an endovascular rat glioma model, this study aimed to analyze the efficacy of intra-arterial (IA) carboplatin and bevacizumab delivery with blood-brain barrier breakdown (BBBB) for glioblastoma treatment.C6-glioma cells were stereotactically injected into the left frontal lobe of Wistar rats. Tumor growth was confirmed on day 8 via MRI. On day 9, a microcatheter was navigated under fluoroscopy from the left femoral artery to the left internal carotid artery. A volume of 2.25 mL of 25% mannitol was administered, followed by either 10 mg/kg of bevacizumab or 2.4 mg/kg of carboplatin. Serial MRI was obtained post-treatment to assess tumor response via analysis of tumor size and radiomics. Histology was analyzed after termination.Control tumor rats and IA mannitol treated tumor rats had fatal tumor growths, with survival until 19.75±2.21 and 36.3±15.1 days, respectively. Carboplatin and bevacizumab treated rats lived >40 days, after which they were euthanized. From serial MRI and histology, IA carboplatin treated rats exhibited tumor regression and resolution by day 35. In IA bevacizumab treated rats, there was tumor regression near the basal ganglia of the brain, closer to the IA chemotherapy injection site, which had reorganized growth patterns. From MRI, 29 unique radiomic features were significantly different between control and treated tumors (notably for total energy and skewness), and treatment responders had a distinct, early manifesting radiomic profile.IA carboplatin and bevacizumab treatment resulted in varying degrees of tumor suppression, validating the first endovascular C6 glioma model as a reliable method to assess new IA therapies.© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.